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Abstract-Female sexual arousal disorder (FSAD) is one of the subcategories of female sexual dysfunction (FSD). During recent years, 
many different chemical and herbal medicines have been introduced to the market by pharmaceutical companies targeting women 
who suffer sexual dysfunction. Notwithstanding, the majority of these medications failed to demonstrate their efficacy in 
experimental studies. Regarding the fact that men and women are increasingly becoming similar in terms of life style, familial and 
social responsibilities, etc, treating female sexual problems by the use of sildenafil citrate (Viagra) has become of interest to many 
physicians and professionals. This drug is a phosphodiesterase type 5 inhibitor and is commonly used for the treatment of erectile 
dysfunction. Evaluation of the effect of sildenafil on FSAD has yielded controversial results and still there is no unanimity on this 
issue. The focus of this review article is on the efficacy of sildenafil as a treatment for FSAD. Regarding the fact that women’s sexual 
dysfunction is a biopsychosocial disorder with a multifaceted etiology, it is proposed that the sole use of sildenafil may not be an 
effective treatment for FSAD. All aspects of female sexuality should be taken into account during evaluation of female sexual 
function and when therapeutic approaches for FSAD are introduced. As a matter of fact, women’s sexual problems may become 
worse and their self-confidence may be negatively affected if improper treatment approach is nominated.  
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I. INTRODUCTION 
Sexual response cycle includes four main elements, namely desire, arousal (excitement), orgasm and resolution [1]. Each 
domain of sexual response cycle can be deteriorated by many factors and result in  sexual dysfunction, which is described as 
“an inability to perform or reach an orgasm, painful sexual intercourse, a strong repulsion of sexual activity, or an exaggerated 
sexual response cycle or sexual interest” [2]. The prevalence of female sexual dysfunction (FSD) among general population has 
been reported to vary  from 31.5% [3], 43% [4], 46.9% [5], to 91% [6]. Female sexual arousal disorder (FSAD) is one of the most 
prevalent sub-categories of FSD (Table I) [2, 7-11] that has been reported to affect 10-76.1% of women of all ages [6, 12, 13].  
TABLE I CATEGORIES OF SEXUAL DYSFUNCTION IN WOMEN 
Type of Sexual Dysfunction Description 
Sexual Interest/Desire Disorder 
Lack of or diminished sexual interest, sexual thoughts or fantasies, 
responsive desire motivation scarce or absent. 
Lack of interest beyond what naturally occurs with age and 
duration of relationship. 
Subjective Sexual Arousal 
Disorder 
Sexual stimulation results in little to no feelings of sexual arousal; 
however, vaginal lubrication and other physical responses occur. 
Subjective Genital Arousal 
Disorder 
Diminished or lack of genital sexual arousal such as vaginal 
lubrication or vulval swelling from any type of sexual stimulation; 
nongenital stimuli still cause subjective sexual excitement. 
Combined Genital and 
Subjective Arousal Disorder 
Sexual stimulation results in little to no feelings of sexual arousal 
in addition to lack of or impaired genital arousal such as vaginal 
lubrication. 
Persistent Sexual Arousal 
Disorder 
Spontaneous genital throbbing, tingling, pulsating that is 
unrelieved by orgasm and occurs in the absence of sexual interest 
and desire. 
Feelings of arousal occur for hours to days. 
Women's Orgasmic Disorder Absence of, diminished intensity of, or delay of orgasm from stimulation. 
Vaginismus 
Difficulty allowing vaginal entry of the penis, finger, or other 
objects despite the woman's desire to do so; usually occurs with 
involuntary pelvic muscle contractions and may be accompanied 
by avoidance, fear, and/or anxiety. 
Dyspareunia Recurrent pain with attempted or complete entry into the vagina. 
Sexual Aversion Disorder 
Feelings of disgust, fear, or anxiety regarding anticipation or 
attempt at sexual activity, which usually leads to avoidance; may 
be derived from a history of physical or sexual abuse or childhood 
trauma. 
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Table I was reprinted from: Brown, D., Kyle, J., & Ferrill, M. (2009). Assessing the clinical efficacy of sildenafil for the 
treatment of female sexual dysfunction. Annals of Pharmacotherapy, 43(7), 1275-1285; with written permission from the 
publisher (Greg Johnson, Advertising and Marketing Manager of The Annals of Pharmacotherapy).  
Women’s sexuality was strongly suppressed during the Victorian era. They were regarded to lack sexual feeling or were 
expected to avert their desire for sex. During this period of history, women who enjoyed sex or were sexually active were 
known to be unusual individuals with odd personalities. They were doomed to be hospitalized, receiving medications or 
psychotherapy, and in many cases undergoing female genital mutilation [14].  
Recent years, however, have been the age of revolution in the achievement of women’s rights. Advocators have made 
appropriate movements in order to show that women should feel free to express their sexual feelings as well as men. They need 
to have joyful sexual activities and must have access to therapeutic options for their sexual difficulties. This resulted in the 
introduction of both herbal and chemical medicines by many pharmaceutical companies. Nevertheless, experimental studies 
have revealed that not all introduced medicines are successful in the treatment of female sexual dysfunction [15].  
Women’s sexual problems has been recently targeted to be treated by the use of  drugs that have primarily been used to 
treat male sexual dysfunction [16]. The possible reasons behind this may be the followings: i) in nowadays societies, men and 
women are becoming more similar in terms of various aspects of life including life style, familial and social responsibilities, 
etc; ii) the physiology of genital smooth muscle of male and female are almost similar at the time of exposure to sexual stimuli; 
iii) the prevalence of sexual problems is higher among women than men based on the reports of numerous studies from 
multiple countries [4, 17, 18].  
Sildenafil citrate (Viagra) is one of the medicines that is primarily identified as an effective treatment for male erectile 
dysfunction (ED). Its therapeutic effect on ED was accidentally discovered when it was prescribed to male angina patients and 
the majority of patients reported having strong erection after taking the medicine [19]. Due to its success in the treatment of 
male erectile dysfunction, scientists have been tempted to investigate the effect of sildenafil on females sexual arousal disorder 
since 1996 [11]. Nevertheless, different studies have reported controversial findings and the use of sildenafil in the treatment of 
female sexual problems is still a debatable issue.  
This article aims to review available literature on the application of sildenafil in the treatment of female sexual arousal 
disorder. The paper also endeavours to come up with a conclusion whether this medication can be considered as a miracle for 
women suffering arousal disorder or not. 
II. SEXUAL RESPONSE CYCLE AND MECHANISM OF AROUSAL IN MEN AND WOMEN 
Sexual response cycle consists of four main phases including desire, arousal, orgasm, and resolution. Because the main 
focus of this article is on the arousal phase which is expected to be affected by sildenafil, physiological changes during this 
phase in men and women will be discussed first. 
A. Male Physiological Changes during Arousal Phase 
Erection of penis, which varies from partially to fully arouse in different men, is the main characteristic of the male arousal 
phase. The rigidity of penis differs from time to time and mainly bases on signals sent by Central Nervous System (CNS) and 
peripheral stimuli. Penile rigidity is  also affected by a complex interaction between neurotransmitters, vasoactive agents and 
endocrine agents [20]. During arousal phase, the penile trabecular smooth muscles relaxation happens under the effect of 
nonadrenergic-noncholinergic autonomic nerves and also the release of nitric oxide (NO) from vascular endothelium into 
penile corpus cavernosum [21]. The creation of cyclic guanosine monophosphate (cGMP) and in turn the commencement of 
smooth muscle relaxation is triggered by NO [22]. As a result, vascular resistance is diminished and blood flows through 
sinusoidal spaces in the paired corpora cavernosa. This process results in the compression of the subtunical venular plexus 
under the tunica albuginea. Consequently, there is a remarkable drop in  the blood outflow followed by penile erection [23]. 
Other changes in the male body during this phase include the dilation of urethral bulbs and the  ascent of testes in scrotum[24]. 
B. Female Physiological Changes during Arousal Phase 
It has been shown that a group of hormones and chemicals influence female arousal. Androgen and estrogen receptors 
facilitate the positive effects of androgens and estrogen, respectively, to create female sexual arousal. In addition, the 
conversion of intracellular testosterone into estrogen, and also cholesterol into sex hormones (neurosteroids) in brain can have 
substantial impacts on sexual arousal of women. The existence of NO synthase in the clitoral tissue of women may also have 
significant influence on female sexual arousal [25, 26]. Hormonal and chemical factors stimulate the dilation of smooth muscle 
cells around blood spaces in genital organs and result in the increase of blood inflow. Accordingly, the engorgement of clitoris 
and labia minora, the eversion of labia minora, and the increase of the length and diameter of both vagina and clitoris happen 
that can be considered as the most noticeable changes of genital organs during female sexual arousal [27]. Furthermore, vaginal 
lubrication occurs as a result of ultrafiltration of plasma into vagina. This in turn prohibits painful penile-vaginal insertion, 
facilitates the sperm movement and increases the possibility of fertilization [28]. Vaginal enlargement (due to contraction of 
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smooth muscles) and uterus and cervical ascent (due to contraction of lavator ani muscles) result in “vaginal tenting”  during 
arousal phase [29].  
Timing and duration of the arousal phase of sexual response cycle varies between men and women [30]. It may last from less 
than a minute to over several hours [28] and can be affected by factors including sexual stimulation, Central Nervous System 
(CNS), peripheral neurovascular pathway, hormonal alterations, and many more social, cultural and environmental factors [31]. 
III. IS SILDENAFIL A REAL MIRACLE FOR WOMEN? 
The pathway of NO-cGMP (described in previous section of this paper)  can be blocked by phosphodiesterase type 5 
(PDE5), officially known as sildenafil citrate, and lead in prolonged erection  [26]. Sildenafil citrate has been reported  to 
improve male sexual function and has been approved by the Food and Drug Administration (FDA) on March 27, 1998 to be 
applied for the treatment of male erectile dysfunction [32, 33]. Promotional activities for sildenafil primarily targeted “men of a 
certain age” suffering erectile dysfunction [34]. The promotion was, however, so vigorous that made even young healthy men to 
rush to drugstores in the hope of optimizing their sexual performance with sildenafil [35].  
The positive effect of sildenafil on men’s erectile function inspired researchers across the world to examine the efficacy of 
the drug in the treatment of female sexual arousal disorder (FSAD) [36-38]. Notwithstanding, studies evaluating the effect of 
sildenafil on female sexual functioning have yielded controversial results and even in some cases their findings are devastating.  
A. Studies Supporting the Efficacy of Sildenafil in the Treatment of FSD 
In an American placebo controlled study [39], 202 postmenopausal women with FSAD were allocated to two groups to 
received either sildenafil (50 mg, adjustable) or placebo. Findings of the study demonstrated that women with FSAD who did 
not have concomitant hypoactive sexual desire disorder (HSDD) received sildenafil showed more improvement in their sexual 
function than their placebo receiving counterparts did(p<0.02). Women who suffered both HSDD and FSAD did not show 
significant changes in their sexual functioning after taking medications. Berman et al. declared that sildenafil can be a proper 
treatment for women who only have arousal disorder without hypoactive sexual desire disorder. Nevertheless, the potential 
causes of FSAD in the participants were not explored. Moreover, the existence of any psychological and/or neurological 
impairment possibly affecting women’s sexual arousal was not investigated. The results of the study by Berman et al. might 
not be too surprising if the latter had been the case in the study by Berman et al. Indeed, research has shown that women who 
suffer some kinds of neurological impairment may have a desire for sex but may not experience genital arousal. This group of 
women have been shown to benefit from the prescription of sildenafil as reported by Alexander et al.[40]. In a randomized 
double blind trial in Sweden, 129 women with spinal cord injury (SCI) were recruited and assigned to either sildenafil group 
(study group) or placebo group (control group). With regards to the medicine’s efficacy and also tolerability of the participants, 
different doses of sildenafil from 25 mg to 50 and 100 mg were prescribed. Analysis of the data revealed that both the study 
and control groups showed an increase in the frequency of sexual activities. However, the difference between groups was not 
statistically significant. Sildenafil was able to enhance the scores of sexual function and sexual quality of life with no 
statistically significant differences between groups. Alexander et al. asserted that although sexual function of women with SCI 
may be promoted by the use of sildenafil, this influence might not be too remarkable. 
In a double-blind, placebo-controlled study [41], sexual function of nineteen women, who suffered from spinal cord injury 
(SCI), was investigated. Participants were randomly assigned to either sildenafil-receiving group or placebo-receiving group. 
The vaginal congestion was measured by Vaginal Photoplethysmography method. Results of the study showed that scores for 
subjective arousal significantly increased in sildenafil-receiving group (P <0.01 between groups). The amelioration of sexual 
dysfunction was more striking when a combination of sildenafil and sexual stimulation in addition to visual and manual 
stimulation were applied. Although the increase of vaginal congestion was more remarkable in the sildenafil-receiving group, 
there was no statistically significant difference between groups in this regard (P =0.07). Sipski et al. concluded that sildenafil 
might create partial improvement in sexual dysfunction of women with SCI. 
In a study  by Salerian et al. [42], sixty-one men and thirty-one women, who referred to an outpatient psychiatric clinic, 
received sildenafil to treat their psychotropic-induced sexual problems (doses ranged from 12.5 to 100 mg). Findings of the 
research demonstrated that both men and women showed significant improvement in scores of arousal, libido, orgasm and 
overall sexual satisfaction and there was a statistically significant difference between before and after the intervention in either 
study group.  It seems that the increase of women’s libido in the study by Salerian et al. has been a psychological response to 
sildenafil resulting in the improvement of women’s libido. Earlier research has shown that response to a medication and 
improvement in situation can occur even when individuals receive placebo due to a psychological response to the drug [43]. 
Therefore the promotion of libido in participants in the study by Salerian et al. might have been due to them expecting a 
positive change in their sexual desire after using sildenafil. 
The aim of a placebo-controlled Brazilian study was to investigate clitoral blood flow and sexual function of participants 
[44]. To this aim, twenty-two women were assigned to either sildenafil or placebo group. Results of the study revealed that 
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sildenafil was more effective than placebo in the increase of clitoral blood flow. The frequency of masturbation was higher in 
women taking sildenafil than women taking placebo (p<0.05). Nonetheless, the results of study may not be generalized to a 
larger population due to the small number of participants in the study.  
B. Studies Questioning the Efficacy of Sildenafil in the Treatment of FSD 
In a multiple countries study [45], 583 estrogenized women, 201 estrogen-deficient women, and 108 untreated healthy 
women were assigned to three groups.  The estrogenized group received 10, 50 or 100 mg sildenafil, the estrogen-deficient 
group received 50 mg sildenafil and the healthy women received no medication (control group). It was reported that women 
who received sildenafil did not represent any improvement in their sexual response, and the differences between those who 
received sildenafil and control group were not statistically significant. A literature review article by Wylie et al. [15] also 
reported that prescription of sildenafil has no positive effect on female sexual dysfunction. 
In an American prospective study  [46] thirty-three pre- and postmenopausal women were recruited and were prescribed 
with 50 mg sildenafil. The sexual function of participants was evaluated by the use of Index of Female Sexual Function (IFSF). 
Findings of the study revealed that overall sexual function was not affected by the use of sildenafil in spite of a minor increase 
in the amount of vaginal lubrication and the sensitivity of clitoris. Findings of a double-blind, crossover study by Van Der 
Made [47] demonstrated that when testosterone or vardenafil were used alone, no effects was recorded. Nevertheless, when a 
combination of the medications was administered, significant changes were observed. In addition, women who primarily had 
high level of attention for sexual cues did not respond to the combination of the drugs. In contrast, women who primarily had 
low attention for sexual cues, significantly responded to the combination of testosterone and vardenafil and showed higher 
improvement in genital lubrication and also subjective vaginal arousal.  
The philosophy behind the use of sildenafil in the improvement of quality of sexual life of women may be the assumption 
that men and women have identical sexual response cycle, and that the enhancement of genital vasocongestion and vaginal 
lubrication with the use of sildenafil may positively affect female psychological sexual arousal [48]. These assumption are 
mainly based on the primary model of sexual response cycle suggested by William Masters and Virginia Johnson in 1966 [49]. 
The assumption is justified as follows: physical response to sexual stimuli is significantly associated with individual’s 
subjective sexual arousal and her psychological inclination to initiate sexual activity. In other words, having genital response to 
the medication is a symptom of individual’s psychological sexual arousal [48, 50]. This assumption seems to be unrealistic as 
subjective sexual arousal in women consists of mental sexual arousal, enhanced sensitivity of genital and nongenital areas in 
response to sexual stimuli, having a sense of genital congestion, awareness of vaginal lubrication and other changes in the body. 
It is associated with informed sexual desire and pleasure [51, 52]. 
Men and women have been reported to differ in terms of subjective and physiological aspects of sexual response. Male’s 
physiological genital response is usually in accordance with his subjective sexual response. While, there is sometimes 
disagreement between female’s subjective and physiologic sexual response. Women who suffer sexual dysfunction represent 
lower concordance between their subjective and physiologic sexual response. This suggests that genital and subjective sexual 
arousal disagreement of women may be a significant indicator of their sexual dysfunction and may particularly be related to 
sexual arousal disorder [53-55]. 
It has been shown that female genital response may be provoked by a broad spectrum of stimuli without any subjective 
sexual arousal. Administration of some medicines such as sildenafil may result in genital response and vaginal lubrication in 
laboratory, but it does not necessarily mean that subjective sexual arousal has occurred and that the individual is experiencing a 
sexually arousing stimulus [56, 57]. Evidence to this claim is the reports by sexually assaulted women who have experienced 
genital response, vasocongestion and orgasm during the assault. This may justify that the vaginal vasocongestion may be 
initiated in the absence of a conscious feeling of sexual arousal [48].  
It has been suggested that the frequency of sexual activities in men suffering erectile dysfunction may not be greatly 
influenced by the use of sildenafil [58], and that without having relationship satisfaction men may not claim that sildenafil is the 
messenger of sexual happiness [59]. These reports suggest that in order for sildenafil to be effective and to work properly, there 
is substantial need for primary sexual desire.  
These explanations may help to understand why some medications such as sildenafil may not help to improve sexual 
arousal disorder in women, as the problem may be a result of discordance between subjective and physiologic sexual response. 
Studies evaluating the effects of medications on female sexual function have reported that drugs may significantly induce 
genital arousal, but they may not change the self-reported sexual arousal [60, 61]. Sildenafil has been made to boost genital 
vasocongestion but not to improve the desire for sex or promote the psychological sexual arousal. Although perception of 
increased genital stimulation may be enhanced with the use of sildenafil [39, 62], it may, in turn, enhance the discordance and 
induce sexual aversion [46], orgasmic dysfunction [62, 63] or hypersensitivity of clitoris [39]. 
Other aspect of medication prescription that must be taken into consideration is the drug’s side effects. It has been reported 
that the use of sildenafil may leave individuals with consequences that may put its application under question. Both men and 
women have been reported to experience side effects after using sildenafil in many clinical trials. Some of the side effects of 
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sildenafil include but not limited to flushing, headache, abnormal vision, vasodilatation, dyspepsia, nasal congestion, muscle 
pain, sedation, and low diastolic blood pressure  [40, 45, 64-66]. In some studies the severity of consequences has increased parallel 
to the increase of the dose of sildenafil. In addition, reports of a few studies have revealed that even some patients had to stop 
taking sildenafil due to experiencing severe side effects [45, 67]. 
IV. COMMENTS AND CONCLUSION 
The recent breakthroughs in medical sciences and the increasing variety of medications have helped elongate people’s life 
and promote their quality of life. Nevertheless, the growing use of chemical medicines to resolve all kinds of diseases, 
dysfunctions and difficulties seems to be a problem of societies in the 21st century [68]. These days, societies are witnessing the 
increasing similarity between men and women regarding their responsibilities and abilities in both familial and societal levels. 
Nonetheless, it should not be taken for granted that men and women still possess basic biological differences. Regarding the 
fact that many different root causes may contribute to female sexual dysfunction, female sexual dysfunction must be 
distinguished from male sexual dysfunction and the treatment of sexual problems of women needs to be regarded 
independently and carefully[8].  
Sildenafil is a chemical substance whose mechanism of action in most men and minority of women is through controlling a 
physiological process. It is not the potion of intimacy and love. What sildenafil does is similar to many antidepressants which 
only suppress the demonstration of psychological symptoms and do not eradicate the main causes inducing psychological 
problems [34]. More than forty years ago, it was asserted that psychogenic etiology is responsible for 90% of cases of sexual 
dysfunction and only 10% of sexual dysfunction cases result from organic causes [69]. However, after the introduction of 
sildenafil citrate to market during last decade, new statistics interestingly report that 80% of sexual problems are rooted back in 
organic dysfunction, while, psychological problems are the cause of 20% of sexual difficulties [70, 71].  
In spite of the isolation of PDE5 from the penis in men and  smooth muscle of the clitoris [26], its existence in the vagina is 
still under question and there has been no unanimity on the issue by today. Women’s sexual arousal – including vaginal 
vasocongestion and lubrication – differs from male arousal and has different physiological process, as the main factors 
inducing penile erection has been known to be NO. Although some researchers believe that vaginal vasocongestion and 
lubrication is substantially affected by NO [72, 73], other research has reported that women carry very low levels of NO 
synthetase in their blood vessels than men do, and this substance is almost undetectable in menopausal women [74]. Therefore, 
sexual arousal of women appears not to be significantly influenced by sildenafil [75]. 
Because general well-being and quality of life of women may be highly affected by any impairment in their normal sexual 
functioning and elements of sexual response cycle [61, 76], it is necessary to resolve sexual problems of women considering 
appropriate treatment approaches for either sex, male or female. Pharmaceutical companies magnify and sometime exaggerate 
the effect of sildenafil on the enhancement of men’s self-confidence indicating that it can optimize their sexual functioning. 
Nevertheless, this review article suggests that self-confidence of women may decrease after using sildenafil as they may notice 
no positive change in their sexual functioning. Having low level of sexual desire or arousal may not be perceived as a 
dysfunction by some women. But, if they are told that their low level of desire, arousal, or not reaching orgasm is a 
dysfunction, they may become less confident. They may even become more devastated after using sildenafil and not seeing 
any positive changes.  
Sexual dysfunction of women is not a mere physiologic event. In fact, it is influenced by many internal and external factors 
including psychosocial, biological, and hormonal factors. It is also noteworthy to mention that there are many various ways to 
promote the quality of sexual life of women other than using chemical medications. Sildenafil should be the last option and 
must be used only for the right cases as not all women may benefit from its use.  
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